4131 Stock Overview
Designs, manufactures, and sells biochips and rapid nucleic acid hybridization devices.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NeoCore Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$31.30 |
| 52 Week High | NT$38.00 |
| 52 Week Low | NT$20.80 |
| Beta | 0.29 |
| 11 Month Change | -0.63% |
| 3 Month Change | -4.28% |
| 1 Year Change | 15.29% |
| 33 Year Change | 90.04% |
| 5 Year Change | 112.69% |
| Change since IPO | -70.25% |
Recent News & Updates
Shareholder Returns
| 4131 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -2.2% | 1.1% | 4.6% |
| 1Y | 15.3% | 0.6% | 34.3% |
Return vs Industry: 4131 exceeded the TW Biotechs industry which returned 0.6% over the past year.
Return vs Market: 4131 underperformed the TW Market which returned 34.3% over the past year.
Price Volatility
| 4131 volatility | |
|---|---|
| 4131 Average Weekly Movement | 3.3% |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.4% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 4131 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4131's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | n/a | www.bio-drchip.com.tw |
NeoCore Technology Co., Ltd. designs, manufactures, and sells biochips and rapid nucleic acid hybridization devices. The company’s products include food safety examination systems, human diagnosis arrays systems, agriculture examination systems, food examination arrays systems, and laboratory instruments, as well as DNA kits. It also offers laboratory planning, design, and other services.
NeoCore Technology Co., Ltd. Fundamentals Summary
| 4131 fundamental statistics | |
|---|---|
| Market cap | NT$1.24b |
| Earnings (TTM) | -NT$70.66m |
| Revenue (TTM) | NT$60.77m |
20.3x
P/S Ratio-17.5x
P/E RatioIs 4131 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4131 income statement (TTM) | |
|---|---|
| Revenue | NT$60.77m |
| Cost of Revenue | NT$72.47m |
| Gross Profit | -NT$11.70m |
| Other Expenses | NT$58.96m |
| Earnings | -NT$70.66m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.79 |
| Gross Margin | -19.25% |
| Net Profit Margin | -116.28% |
| Debt/Equity Ratio | 17.9% |
How did 4131 perform over the long term?
See historical performance and comparison